Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

Purpose TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2017-02, Vol.19 (2), p.227-235
Main Authors: Longo-Muñoz, F., Argiles, G., Tabernero, J., Cervantes, A., Gravalos, C., Pericay, C., Gil-Calle, S., Mizuguchi, H., Carrato-Mena, A., Limón, M. L., Garcia-Carbonero, R.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antiviral Agents - therapeutic use
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - secondary
Double-Blind Method
Drug Combinations
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Staging
Oncology
Palliative Care
Prognosis
Research Article
Spain
Survival Rate
Trifluridine - therapeutic use
Uracil - analogs & derivatives
Uracil - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. Results of RECOURSE demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 versus placebo [hazard ratio (HR) = 0.68 and 0.48 for OS and PFS, respectively; both P  
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-016-1528-7